| Literature DB >> 28874313 |
Javier Ampuero1, Yolanda Sánchez-Torrijos1, Virginia Aguilera1, Francisco Bellido2, Manuel Romero-Gómez3.
Abstract
Management of non-alcoholic steatohepatitis is focused on restitution of metabolic derangement, weight loss and drugs able to improve steatosis, ballooning and fibrosis. Life-style interventions based on Mediterranean diet and increasing physical activity are the first line therapy. In patients with unsuccessful life-style intervention several drugs are under development: agonist PPAR, agonist GLP-1R and agonist FXR together with drugs focussing on inflammation, ballooning, apoptosis and fibrosis. Bariatric surgery or advanced endoscopy are reserved for morbid obese without response to life-style intervention and weighting loss drugs.Entities:
Keywords: Agonistas glucagon-like peptide-1 receptor; Body mass index; Glucagon-like peptide-1 receptor agonists; Obesidad visceral; Obeticolic acid; Peroxisome proliferator-activated receptor; Peroxisome proliferator-activated receptors; Visceral obesity; Ácido obeticólico; Índice de masa corporal
Mesh：
Substances：
Year: 2017 PMID： 28874313 DOI： 10.1016/j.gastrohep.2017.07.006
Source DB: PubMed Journal: Gastroenterol Hepatol ISSN： 0210-5705 Impact factor: 2.102